124 related articles for article (PubMed ID: 26316916)
1. Metastatic Renal Cell Cancer: Summary from ASCO 2015.
Can Urol Assoc J; 2015; 9(7-8):S158-61. PubMed ID: 26316916
[No Abstract] [Full Text] [Related]
2. Rate of reclassification of HER2-equivocal breast cancer cases to HER2-negative per the 2018 ASCO/CAP guidelines and response of HER2-equivocal cases to anti-HER2 therapy.
Crespo J; Sun H; Wu J; Ding QQ; Tang G; Robinson MK; Chen H; Sahin AA; Lim B
PLoS One; 2020; 15(11):e0241775. PubMed ID: 33180796
[TBL] [Abstract][Full Text] [Related]
3. Guideline on Muscle-Invasive and Metastatic Bladder Cancer (European Association of Urology Guideline): American Society of Clinical Oncology Clinical Practice Guideline Endorsement.
Milowsky MI; Rumble RB; Booth CM; Gilligan T; Eapen LJ; Hauke RJ; Boumansour P; Lee CT
J Clin Oncol; 2016 Jun; 34(16):1945-52. PubMed ID: 27001593
[TBL] [Abstract][Full Text] [Related]
4. Cancer immunotherapy highlights from the 2014 ASCO Meeting.
Harshman LC; Drake CG; Wargo JA; Sharma P; Bhardwaj N
Cancer Immunol Res; 2014 Aug; 2(8):714-9. PubMed ID: 25092813
[TBL] [Abstract][Full Text] [Related]
5. What's new in renal cell cancer research? Highlights of GU-ASCO 2014.
Kapoor A
Can Urol Assoc J; 2014 Mar; 8(3-4 Suppl 2):S13-5. PubMed ID: 24860631
[TBL] [Abstract][Full Text] [Related]
6. The value measurement of emerging therapeutics in renal cell carcinoma: ASCO value framework and ESMO-MCBS.
Ha H; Kang JH; Kim DY; Bae SJ; Lee HY
BMC Health Serv Res; 2022 Jul; 22(1):900. PubMed ID: 35821026
[TBL] [Abstract][Full Text] [Related]
7. ASCO Plenary Sessions: impact, legacy, future.
Vandross A; Prasad V; Mailankody S
Semin Oncol; 2016 Jun; 43(3):321-6. PubMed ID: 27178681
[TBL] [Abstract][Full Text] [Related]
8. Anticonvulsant prophylaxis and steroid use in adults with metastatic brain tumors: summary of SNO and ASCO endorsement of the Congress of Neurological Surgeons guidelines.
Chang SM; Messersmith H; Ahluwalia M; Andrews D; Brastianos PK; Gaspar LE; Gatson NN; Jordan JT; Khasraw M; Lassman AB; Maues J; Mrugala M; Raizer J; Schiff D; Stevens G; Sumrall A; Van den Bent M; Vogelbaum MA
Neuro Oncol; 2019 Mar; 21(4):424-427. PubMed ID: 30883663
[TBL] [Abstract][Full Text] [Related]
9. [Progress and summary of recent congress: ASCO-GU, EAU, AUA, ASCO about the medical management of locally advanced or metastatic kidney cancer].
Patard JJ; Escudier B; Paparel P; Neuzillet Y; Long JA; Baumert H; Correas JM; Lang H; Poissonnier L; Rioux-Leclercq N; Soulié M;
Prog Urol; 2010 Mar; 20 Suppl 1():S11-5. PubMed ID: 20493436
[TBL] [Abstract][Full Text] [Related]
10. Clinical benefit and cost of breakthrough cancer drugs approved by the US Food and Drug Administration.
Molto C; Hwang TJ; Borrell M; Andres M; Gich I; Barnadas A; Amir E; Kesselheim AS; Tibau A
Cancer; 2020 Oct; 126(19):4390-4399. PubMed ID: 32697362
[TBL] [Abstract][Full Text] [Related]
11. Management of Metastatic Clear Cell Renal Cell Carcinoma: ASCO Guideline.
Rathmell WK; Rumble RB; Van Veldhuizen PJ; Al-Ahmadie H; Emamekhoo H; Hauke RJ; Louie AV; Milowsky MI; Molina AM; Rose TL; Siva S; Zaorsky NG; Zhang T; Qamar R; Kungel TM; Lewis B; Singer EA
J Clin Oncol; 2022 Sep; 40(25):2957-2995. PubMed ID: 35728020
[TBL] [Abstract][Full Text] [Related]
12. Role of Circulating Tumor DNA in Gastrointestinal Cancers: Update From Abstracts and Sessions at ASCO 2018.
Shahjehan F; Kamatham S; Kasi PM
Front Oncol; 2019; 9():358. PubMed ID: 31139561
[No Abstract] [Full Text] [Related]
13. Management of Metastatic Clear Cell Renal Cell Carcinoma: ASCO Guideline Q&A.
Singer EA; Rumble RB; Van Veldhuizen PJ
JCO Oncol Pract; 2023 Mar; 19(3):127-131. PubMed ID: 36595734
[No Abstract] [Full Text] [Related]
14. 2021 ASCO genitourinary cancers symposium: a focus on renal cell carcinoma.
Iacovelli R; Cannella MA; Ciccarese C; Astore S; Foschi N; Palermo G; Tortora G
Expert Rev Anticancer Ther; 2021 Nov; 21(11):1203-1206. PubMed ID: 34482771
[TBL] [Abstract][Full Text] [Related]
15. 2007 Update of ASCO Practice Guideline for the Initial Hormonal Management of Androgen-Sensitive Metastatic, Recurrent, or Progressive Prostate Cancer: Guideline Summary.
J Oncol Pract; 2007 May; 3(3):175-177. PubMed ID: 29455596
[No Abstract] [Full Text] [Related]
16. Inside the 2015 ASCO Genitourinary Cancers Symposium.
Santoni M; Massari F; Iacovelli R; Ciccarese C; Verri E; Burattini L; Montironi R; Nolè F; Tortora G; Cascinu S
Future Oncol; 2015; 11(13):1859-62. PubMed ID: 26161923
[TBL] [Abstract][Full Text] [Related]
17. Choosing PD-1 Inhibitors in Oncology Setting, Left or Right?-Lessons From Value Assessment With ASCO-VF and ESMO-MCBS.
Jiang Q; Feng M; Li Y; Lang J; Wei H; Yu T
Front Pharmacol; 2020; 11():574511. PubMed ID: 33390946
[No Abstract] [Full Text] [Related]
18. Anticonvulsant Prophylaxis and Steroid Use in Adults With Metastatic Brain Tumors: ASCO and SNO Endorsement of the Congress of Neurological Surgeons Guidelines.
Chang SM; Messersmith H; Ahluwalia M; Andrews D; Brastianos PK; Gaspar LE; Gatson NTN; Jordan JT; Khasraw M; Lassman AB; Maues J; Mrugala M; Raizer J; Schiff D; Stevens G; Sumrall A; van den Bent M; Vogelbaum MA
J Clin Oncol; 2019 May; 37(13):1130-1135. PubMed ID: 30883246
[TBL] [Abstract][Full Text] [Related]
19. Metastatic Pancreatic Cancer: ASCO Guideline Update.
Sohal DPS; Kennedy EB; Cinar P; Conroy T; Copur MS; Crane CH; Garrido-Laguna I; Lau MW; Johnson T; Krishnamurthi S; Moravek C; O'Reilly EM; Philip PA; Pant S; Shah MA; Sahai V; Uronis HE; Zaidi N; Laheru D
J Clin Oncol; 2020 Sep; 38(27):3217-3230. PubMed ID: 32755482
[TBL] [Abstract][Full Text] [Related]
20. Bone Health and Bone-Targeted Therapies for Prostate Cancer: ASCO Endorsement of a Cancer Care Ontario Guideline.
Saylor PJ; Rumble RB; Tagawa S; Eastham JA; Finelli A; Reddy PS; Kungel TM; Nissenberg MG; Michalski JM
J Clin Oncol; 2020 May; 38(15):1736-1743. PubMed ID: 31990618
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
